'Low-risk' myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro- versus anti-apoptotic bcl-2-related proteins

British Journal of Haematology

Volumn 103, Issue 4, 1998, Pages 1075-1082

  Parker, J E ^a   Fishlock, K L ^a   Mijovic, A ^a   Czepulkowski, B ^a   Pagliuca, A ^a   Mufti, G J ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Acute myeloid leukaemia; Annexin V; Apoptosis; Bcl 2; Myelodysplastic syndrome

Indexed keywords

ANNEXIN; PROTEIN BCL 2;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER RISK; CYTOGENETICS; FEMALE; FLOW CYTOMETRY; GENETIC ANALYSIS; HUMAN; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ANNEXIN A5; ANTIGENS, CD34; APOPTOSIS; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 0032437584     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1998.01114.x     Document Type: Article

References (30)

1. Banker, D.E., Groudine, M., Norwood, T. & Appelbaum, F.R. (1997) Measurement of spontaneous and therapeutic agent-induced apoptosis with BCL-2 protein expression in acute myeloid leukemia. Blood, 89, 243-255.
2. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A., Gralnick, H.R. & Sultan, C. (1982) Proposals for the classification of the myelodysplastic syndromes. British Journal of Haematology, 51, 189-199.
3. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A., Gralnick, H.R. & Sultan, C. (1985) Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Annals of Internal Medicine, 103, 620-625.
4. Bogdanovic, A.D., Trpinac, D.P., Jankovic, G.M., Bumbasirevic, V.Z., Obradovic, M. & Colovic, M.D. (1997) Incidence and role of apoptosis in myelodysplastic syndrome: morphological and ultrastructural assessment. Leukemia, 11, 656-659.
5. Bouscary, D., De Vos, J., Guesnu, M., Jondeau, K., Viguier, F., Melle, J., Picard, F., Dreyfus, F. & Fontenay-Roupie, M. (1997) Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia, 11, 839-845.
6. Bradbury, D.A., Zhu, Y.M. & Russell, N.H. (1997) Bcl-2 expression in acute myeloblastic leukaemia: relationship with autonomous growth and CD34 antigen expression. Leukemia and Lymphoma, 24, 221-228.
7. Campos, L., Rouault, J.P., Sabido, O., Oriol, P., Roubi, N., Vasselon, C., Archimbaud, E., Magaud, J.P. & Guyotat, D. (1993) High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood, 81, 3091-3096.
8. Cortelezzi, A., Di Stefano, M., Sarina, B., Giannini, S., Pomati, M., Silvestris, I., Cattaneo, C., Lambertenghi, D., Cristiani, S. & Maiolo, A.T. (1996) Apoptosis in myelodysplastic syndromes (MDS): putative role of the Bcl-2 proto-oncogene. Blood, 88, 95a.
9. Delia, D., Aiello, A., Soligo, D., Fontanella, E., Melani, C., Pezzella, F., Pierotti, M.A. & Della-Porta, G. (1992) Bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells. Blood, 79, 1291-1298.
10. De-Witte, T., Muus, P., De-Pauw, B. & Haanen, C. (1989) Intensive chemotherapy for patients with myelodysplastic syndromes and acute myelogenous leukemia younger than 65 years. Bone Marrow Transplantation, 4, 33-35.
11. Fenaux, P., Morel, P., Rose, C., Lai, J.L., Jouet, J.P. & Bauters, F. (1991) Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. British Journal of Haematology, 77, 497-501.
12. Greenberg, P., Cox, C., LeBeau, M.M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G. & Bennett, J. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, 2079-2088.
13. Greenberg, P.L., Ginzton, N., Rajapaksa, R., Tong, C.R. & Han, J.H. (1994) Apoptosis in myelodysplastic syndrome (MDS). Blood, 84, 159a.
14. Hellstrom-Lindberg, E., Kanter-Lewensohn, L. & Ost, A. (1997) Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin. Leukemia Research, 21, 415-425.
15. Kitagawa, M., Yamaguchi, S., Takahashi, M., Tanizawa, T., Hirokawa, K. & Kamiyama, R. (1998) Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia. Leukemia, 12, 486-492.
16. Kliche, K.O. & Andreef, M. (1997) High expression of phosphatidylserine (PS) in MDS, secondary AML (sAML) and normal progenitors: comparison with primary AML (pAML). Blood, 90, 202a.
17. Koopman, G., Reutelingsperger, C.P., Kuijten, G.A., Keehnen, R.M., Pals, S.T. & van-Oers, M.H. (1994) Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood, 84, 1415-1420.
18. Krajewska, M., Krajewski, S., Epstein, J.I., Shabaik, A., Sauvageot, J., Song, K., Kitada, S. & Reed, J.C. (1996) Immunohistochemical analysis of bcl-2, bax, bcl-x, and mcl-1 expression in prostate cancers. American Journal of Pathology, 148, 1567-1576.
19. Lima, M., Teixeira, M., dos, A., Morais, S., Cunha, M., Coutinho, J., Pinho, L., Ribeiro, P. & Justica, B. (1995) Immunophenotypic characteristics of acute leukaemia after myelodysplastic syndromes. Sangre (Barcelona), 40, 49-52.
20. Martin, S.J., Reutelingsperger, C.P., McGahon, A.J., Rader, J.A., van-Schie, R.C., LaFace, D.M. & Green, D.R. (1995) Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. Journal of Experimental Medicine, 182, 1545-1556.
21. Mufti, G.J. & Galton, D.A. (1986) Myelodysplastic syndromes: natural history and features of prognostic importance. Clinical Haematology, 15, 953-971.
22. O'Brien, I.E., Reutelingsperger, C.P. & Holdaway, K.M. (1997) Annexin-V and TUNEL use in monitoring the progression of apoptosis in plants. Cytometry, 29, 28-33.
23. Rajapaksa, R., Ginzton, N., Rott, L.S. & Greenberg, P.L. (1996) Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood, 88, 4275-4287.
24. Raza, A., Gezer, S., Mundle, S., Gao, X.Z., Alvi, S., Borok, R., Rifkin, S., Iftikhar, A., Shetty, V., Parcharidou, A., Loew, J., Marcus, B., Khan, Z., Chaney, C., Showel, J., Gregory, S. & Preisler, H. (1995) Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood, 86, 268-276.
25. Stoetzer, O.J., Nussler, V., Darsow, M., Gullis, E., Pelka-Fleischer, R., Scheel, U. & Wilmanns, W. (1996) Association of bcl-2, bax, bcl-xL and interleukin-1 beta-converting enzyme expression with initial response to chemotherapy in acute myeloid leukemia. Leukemia, 10, S18-S22.
26. Ter-Harmsel, B., Smedts, F., Kuijpers, J., Jeunink, M., Trimbos, B. & Ramaekers, F. (1996) BCL-2 immunoreactivity increases with severity of CIN: a study of normal cervical epithelia, CIN, and cervical carcinoma. Journal of Pathology, 179, 26-30.
27. + cells. Experimental Hematology, 26, 53-62.
28. Vermes, I., Haanen, C., Steffens-Nakken, H. & Reutelingsperger, C. (1995) A novel assay for apoptosis: flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. Journal of Immunological Methods, 184, 39-51.
29. Yang, E. & Korsmeyer, S.J. (1996) Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood, 88, 386-401.
30. Yoshida, Y. (1993) Hypothesis: apoptosis may be the mechanism responsible for the premature intramedullary cell death in the myelodysplastic syndrome. Leukemia, 7, 144-146.